| Literature DB >> 31209181 |
Wai-Kin Chan1, Thomas D Horvath1, Lin Tan1, Todd Link2, Karine G Harutyunyan3, Michael A Pontikos1, Andriy Anishkin4, Di Du1, Leona A Martin1, Eric Yin1, Susan B Rempe5, Sergei Sukharev4, Marina Konopleva3, John N Weinstein1, Philip L Lorenzi6.
Abstract
We and others have reported that the anticancer activity of L-asparaginase (ASNase) against asparagine synthetase (ASNS)-positive cell types requires ASNase glutaminase activity, whereas anticancer activity against ASNS-negative cell types does not. Here, we attempted to disentangle the relationship between asparagine metabolism, glutamine metabolism, and downstream pathways that modulate cell viability by testing the hypothesis that ASNase anticancer activity is based on asparagine depletion rather than glutamine depletion per se. We tested ASNase wild-type (ASNaseWT) and its glutaminase-deficient Q59L mutant (ASNaseQ59L) and found that ASNase glutaminase activity contributed to durable anticancer activity against xenografts of the ASNS-negative Sup-B15 leukemia cell line in NOD/SCID gamma mice, whereas asparaginase activity alone yielded a mere growth delay. Our findings suggest that ASNase glutaminase activity is necessary for durable, single-agent anticancer activity in vivo, even against ASNS-negative cancer types. ©2019 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31209181 PMCID: PMC6726508 DOI: 10.1158/1535-7163.MCT-18-1329
Source DB: PubMed Journal: Mol Cancer Ther ISSN: 1535-7163 Impact factor: 6.261